Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
Figure out How to Utilize Your Web based Advertising Degree to Break into the Tech Business - 2Novo and Lilly cut prices of weight-loss drugs in China
- 3The Main 15 Applications for Efficiency and Association
- 44K televisions for Extreme Film Watching Experience
- 56 Hints to Upgrade Your Charm, In addition to Your Mentality
- German Court Rejects Bid To Force BMW and Mercedes-Benz To Stop Selling New Combustion-Engine Cars After 2030
- Find the Effect of Web-based Entertainment on Psychological wellness: Exploring the Advanced Scene Securely
- Embrace Effortlessness: Moderation and Cleaning up Tips
- Trump says Venezuela will start 'turning over' oil to the U.S. Is that the reason he toppled Maduro — or is it something else?
- How did Hugh Jackman nail his latest role? Sequins, tighty-whities and embracing 'zero embarrassment.'
- NASA just launched Artemis 2. What happens today could make or break the moon mission
- Fundamental Home Machines: An Easy to understand Determination Guide
- How 2025 became the year of comet: The rise of interstellar 3I/ATLAS, an icy Lemmon and a cosmic SWAN
- Mojtaba Khamenei unconscious in Qom, not actually running Iran
